ANI Pharmaceuticals enters distribution and supply deal with Aspen

ANI Pharmaceuticals (Nasdaq: ANIP) has signed an exclusive distribution and supply agreement with South Africa’s Aspen Pharmacare (APN: JSE)for hydroxyprogesterone caproate Injection (HPC) USP 250mg/mL in 5mL vials.

Aspen will be responsible for supplying the finished goods and ANI will be responsible for marketing and distribution in the USA. Aspen’s product was approved by Food and Drug Administration in August 2015 and ANI intends to commercialize HPC in the near term.

Aspen, which manufactures the active pharmaceutical ingredient for hydroxyprogesterone caproate (HPC) - previously marketed as Makena by K-V Pharma, announced in December that it had bought the rights to distribute this treatment for female cancers and hormonal imbalances in the world's largest market for pharmaceuticals.